{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Drugs.com Monthly Update Podcast","title":"Drugs.com - Monthly Update July 2025","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/1b0dae97\"></iframe>","width":"100%","height":180,"duration":263,"description":"This month we explore groundbreaking FDA approvals including Ekterly for hereditary angioedema, Anzupgo for chronic hand eczema, and the new dosing regimen of Kisunla for Alzheimer’s. We’ll discuss the mechanisms, patient impacts, and data that drive these advancements.Ekterly (sebetralstat), approved as an oral on-demand treatment for hereditary angioedema (HAE) attacks in patients 12 years and older, providing symptom relief in just 1.6 hours compared to 6.7 hours with placebo.Anzupgo (delgocitinib), the first steroid-free topical treatment approved in the U.S. for moderate to severe chronic hand eczema in adults, working as a pan-Janus kinase inhibitor with twice-daily application to affected areas.Kisunla (donanemab-azbt), now available with an updated once-monthly dosing regimen for early symptomatic Alzheimer's disease, showing a 41% reduction in ARIA-E (amyloid-related imaging abnormalities with edema) at 24 weeks while targeting and removing beta-amyloid plaques in the brain.ChaptersFollow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app","thumbnail_url":"https://img.transistorcdn.com/DIoKA3oI7NY0UzZ45F0V0NkzM-ycfQHBYCciiz9juOc/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMDAz/YzA5MzEzMjc1MDA5/YjRmMjFmMDA1MjYy/YmZmZC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}